Full-dose anticoagulation treatment prevented blood clots in COVID-19 patients

Credit: Pixabay/CC0 Public Domain

A clinical trial of patients with COVID-19 led by investigators at the TIMI Study Group at Brigham and Women's Hospital and the Critical Care Cardiology Trials Network (CCCTN) has found that full-dose anticoagulation lowers the risk of blood clotting complications compared with standard-dose prophylactic anticoagulation. Investigators presented their findings at a Hot Line session at ESC Congress 2022.

Results from previous clinical trials assessing strategies for preventing in patients with COVID-19 have been mixed. The COVID-PACT trial enrolled critically ill patients with COVID-19 from sites across the U.S. Patients were randomized to receive either full-dose or standard-dose prophylactic anticoagulation therapy. A total of 390 patients were randomized to an anticoagulation strategy. Investigators found that the risk of venous or arterial clotting was 44 percent lower among patients who received full-dose compared to standard-dose. Fatal or life-threatening bleeding occurred in four patients in the full-dose group compared to one patient in the standard-dose group.

"Until now, the for preventing blood clots among patients who are critically ill with COVID-19 has remained uncertain," said David Berg, MD, MPH, of the Division of Cardiovascular Medicine. "COVID-PACT shows that, compared with standard-dose prophylaxis, full-dose more effectively prevents the clotting complications of COVID-19."

The research was published in Circulation.

More information: Erin A. Bohula et al, Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT, Circulation (2022). DOI: 10.1161/CIRCULATIONAHA.122.061533

Journal information: Circulation

Citation: Full-dose anticoagulation treatment prevented blood clots in COVID-19 patients (2022, August 29) retrieved 29 March 2023 from https://medicalxpress.com/news/2022-08-full-dose-anticoagulation-treatment-blood-clots.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Prophylactic anticoagulation aids hospitalized COVID-19 patients


Feedback to editors